{"filing":{"accession_number":"0001193125-26-267563","cik":"0001213037","ticker":"CRDF","company_name":"Cardiff Oncology, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"crdf-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526267563/crdf-20260611.htm"},"events":[{"id":5360,"run_id":4696,"accession_number":"0001193125-26-267563","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from Cardiff Oncology's Annual Meeting of Stockholders held on June 11, 2026, filed under Item 5.07. The filing presents final voting tallies for four proposals: election of six directors, ratification of BDO USA as independent auditor, approval of an amendment to the 2021 Equity Incentive Plan, and an advisory vote on named executive officer compensation. All proposals passed with substantial majorities, making this a material routine governance disclosure.","company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6303,"accession_number":"0001193125-26-267563","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Cardiff Oncology's Annual Meeting of Stockholders held on June 11, 2026, filed under Item 5.07. The filing presents final voting tallies for four proposals: election of six directors, ratification of BDO USA as independent auditor, approval of an amendment to the 2021 Equity Incentive Plan, and an advisory vote on named executive officer compensation. All proposals passed with substantial majorities, making this a material routine governance disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:16:41.310180+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6303,"accession_number":"0001193125-26-267563","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Cardiff Oncology's Annual Meeting of Stockholders held on June 11, 2026, filed under Item 5.07. The filing presents final voting tallies for four proposals: election of six directors, ratification of BDO USA as independent auditor, approval of an amendment to the 2021 Equity Incentive Plan, and an advisory vote on named executive officer compensation. All proposals passed with substantial majorities, making this a material routine governance disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:16:41.310180+00:00","company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","filing_date":"2026-06-11"}]}